Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma

I. Garces de Los Fayos Alonso, L. Zujo, I. Wiest, P. Kodajova, G. Timelthaler, S. Edtmayer, M. Zrimšek, S. Kollmann, C. Giordano, M. Kothmayer, HA. Neubauer, S. Dey, M. Schlederer, BS. Schmalzbauer, T. Limberger, C. Probst, O. Pusch, S. Högler,...

. 2022 ; 21 (1) : 172. [pub] 20220831

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024708

BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFRβ. Blocking PDGFRβ kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. METHODS AND RESULTS: In a transgenic mouse model that mimics PDGFRβ-driven human ALCL in vivo, we identify PDGFRβ as a driver of aggressive tumor growth. Mechanistically, PDGFRβ induces the pro-survival factor Bcl-xL and the growth-enhancing cytokine IL-10 via STAT5 activation. CRISPR/Cas9 deletion of both STAT5 gene products, STAT5A and STAT5B, results in the significant impairment of cell viability compared to deletion of STAT5A, STAT5B or STAT3 alone. Moreover, combined blockade of STAT3/5 activity with a selective SH2 domain inhibitor, AC-4-130, effectively obstructs tumor development in vivo. CONCLUSIONS: We therefore propose PDGFRβ as a novel biomarker and introduce PDGFRβ-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFRβ or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK+ ALCL patients.

Boltzmann Institute Applied Diagnostics 1090 Vienna Austria

CBMed Core Lab Medical University of Vienna 1090 Vienna Austria

Center for Cancer Research Medical University of Vienna 1090 Vienna Austria

Center for Medical Research Medical University of Graz 8010 Graz Austria

Central European Institute of Technology Masaryk University Brno Czech Republic

Centre for Anatomy and Cell Biology Medical University of Vienna 1090 Vienna Austria

Christian Doppler Laboratory of Applied Metabolomics Department of Biomedical Imaging and Image guided Therapy Medical University of Vienna 1090 Vienna Austria

Comprehensive Cancer Center Vienna Vienna General Hospital Medical University of Vienna 1090 Vienna Austria

Department of Chemical and Physical Sciences University of Toronto Mississauga Mississauga ON L5L 1C6 Canada

Department of Chemistry University of Toronto Toronto ON M5S 3H6 Canada

Department of Computational Biology St Jude Children's Research Hospital Memphis TN USA

Department of Dermatology Medical University of Graz 8036 Graz Austria

Department of Hematology Oncology and Cancer Immunology Charité Medical University of Berlin 12200 Berlin Germany

Department of Medicine 1 Division of Hematology and Hemostaseology Medical University of Vienna 1090 Vienna Austria

Department of Pathology Hematopathology Section and Lymph Node Registry University of Kiel University Hospital Schleswig Holstein 24105 Kiel Germany

Department of Pathology Medical University of Vienna 1090 Vienna Austria

Department of Pediatric Oncology Dana Farber Cancer Institute Harvard Medical School Boston MA USA

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Cambridge CB20QQ UK

Division of Nuclear Medicine Medical University of Vienna 1090 Vienna Austria

Division Pharmacology Department of Pharmacology Physiology and Microbiology Karl Landsteiner University of Health Sciences 3500 Krems Austria

Experimental and Clinical Research Center a joint cooperation between the Charité and the MDC 13125 Berlin Germany

German Cancer Consortium 69120 Heidelberg Germany

Institute of Animal Breeding and Genetics Unit of Functional Cancer Genomics University of Veterinary Medicine Vienna 1210 Vienna Austria

Institute of Pathology and Neuropathology and Cluster of excellence iFIT Image Guided and Functionally Instructed Tumor Therapy University of Tübingen 72076 Tübingen Germany

Institute of Pathology Charité Medical University of Berlin 10117 Berlin Germany

Institute of Pathology University of Wuerzburg 97080 Würzburg Germany

Institute of Pharmacology and Toxicology University of Veterinary Medicine Vienna 1210 Vienna Austria

Max Delbrück Center for Molecular Medicine 13125 Berlin Germany

Pediatric Hematology and Oncology University Hospital Hamburg Eppendorf Hamburg Germany

Unit of Laboratory Animal Pathology University of Veterinary Medicine Vienna 1210 Vienna Austria

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024708
003      
CZ-PrNML
005      
20240516120031.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-022-01640-7 $2 doi
035    __
$a (PubMed)36045346
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Garces de Los Fayos Alonso, I $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
245    10
$a PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma / $c I. Garces de Los Fayos Alonso, L. Zujo, I. Wiest, P. Kodajova, G. Timelthaler, S. Edtmayer, M. Zrimšek, S. Kollmann, C. Giordano, M. Kothmayer, HA. Neubauer, S. Dey, M. Schlederer, BS. Schmalzbauer, T. Limberger, C. Probst, O. Pusch, S. Högler, S. Tangermann, O. Merkel, AI. Schiefer, C. Kornauth, N. Prutsch, M. Zimmerman, B. Abraham, J. Anagnostopoulos, L. Quintanilla-Martinez, S. Mathas, P. Wolf, D. Stoiber, PB. Staber, G. Egger, W. Klapper, W. Woessmann, TA. Look, P. Gunning, SD. Turner, R. Moriggl, S. Lagger, L. Kenner
520    9_
$a BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFRβ. Blocking PDGFRβ kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. METHODS AND RESULTS: In a transgenic mouse model that mimics PDGFRβ-driven human ALCL in vivo, we identify PDGFRβ as a driver of aggressive tumor growth. Mechanistically, PDGFRβ induces the pro-survival factor Bcl-xL and the growth-enhancing cytokine IL-10 via STAT5 activation. CRISPR/Cas9 deletion of both STAT5 gene products, STAT5A and STAT5B, results in the significant impairment of cell viability compared to deletion of STAT5A, STAT5B or STAT3 alone. Moreover, combined blockade of STAT3/5 activity with a selective SH2 domain inhibitor, AC-4-130, effectively obstructs tumor development in vivo. CONCLUSIONS: We therefore propose PDGFRβ as a novel biomarker and introduce PDGFRβ-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFRβ or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK+ ALCL patients.
650    _2
$a anaplastická lymfomová kináza $7 D000077548
650    _2
$a zvířata $7 D000818
650    _2
$a karcinogeneze $x metabolismus $7 D063646
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a lidé $7 D006801
650    12
$a anaplastický velkobuněčný lymfom $x genetika $x patologie $7 D017728
650    _2
$a myši $7 D051379
650    _2
$a fosforylace $7 D010766
650    12
$a růstový faktor odvozený z trombocytů - receptor beta $x metabolismus $x farmakologie $7 D020797
650    12
$a transkripční faktor STAT3 $x metabolismus $7 D050796
650    12
$a transkripční faktor STAT5 $x genetika $7 D050799
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zujo, L $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Division of Nuclear Medicine, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Wiest, I $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Division of Nuclear Medicine, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kodajova, P $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Timelthaler, G $u Center for Cancer Research, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Edtmayer, S $u Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria
700    1_
$a Zrimšek, M $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kollmann, S $u Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Giordano, C $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kothmayer, M $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Centre for Anatomy and Cell Biology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Neubauer, H A $u Institute of Animal Breeding and Genetics, Unit of Functional Cancer Genomics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Dey, S $u Department of Dermatology, Medical University of Graz, 8036, Graz, Austria $u Center for Medical Research (ZMF), Medical University of Graz, 8010, Graz, Austria
700    1_
$a Schlederer, M $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Schmalzbauer, B S $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Limberger, T $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Division of Nuclear Medicine, Medical University of Vienna, 1090, Vienna, Austria $u CBMed Core Lab, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Probst, C $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Division of Nuclear Medicine, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Pusch, O $u Centre for Anatomy and Cell Biology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Högler, S $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Tangermann, S $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Merkel, O $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Schiefer, A I $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kornauth, C $u Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090, Vienna, Austria $u Comprehensive Cancer Center Vienna, Vienna General Hospital, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Prutsch, N $u Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
700    1_
$a Zimmerman, M $u Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
700    1_
$a Abraham, B $u Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA
700    1_
$a Anagnostopoulos, J $u Institute of Pathology, University of Wuerzburg, 97080, Würzburg, Germany $u Institute of Pathology, Charité-Medical University of Berlin, 10117, Berlin, Germany
700    1_
$a Quintanilla-Martinez, L $u Institute of Pathology and Neuropathology and Cluster of excellence iFIT, "Image-Guided and Functionally Instructed Tumor Therapy", University of Tübingen, 72076, Tübingen, Germany
700    1_
$a Mathas, S $u Department of Hematology, Oncology, and Cancer Immunology, Charité-Medical University of Berlin, 12200, Berlin, Germany $u German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany $u Max-Delbrück-Center (MDC) for Molecular Medicine, 13125, Berlin, Germany $u Experimental and Clinical Research Center, a joint cooperation between the Charité and the MDC, 13125, Berlin, Germany
700    1_
$a Wolf, P $u Department of Dermatology, Medical University of Graz, 8036, Graz, Austria
700    1_
$a Stoiber, D $u Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria
700    1_
$a Staber, P B $u Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090, Vienna, Austria $u Comprehensive Cancer Center Vienna, Vienna General Hospital, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Egger, G $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Comprehensive Cancer Center Vienna, Vienna General Hospital, Medical University of Vienna, 1090, Vienna, Austria $u Boltzmann Institute Applied Diagnostics, 1090, Vienna, Austria
700    1_
$a Klapper, Wolfram, $d 1971- $u Department of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel/University Hospital Schleswig-Holstein, 24105, Kiel, Germany $7 xx0317360
700    1_
$a Woessmann, W $u Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Look, T A $u Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
700    1_
$a Gunning, P $u Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, ON, L5L 1C6, Canada $u Department of Chemistry, University of Toronto, Toronto, ON, M5S 3H6, Canada
700    1_
$a Turner, S D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Moriggl, R $u Institute of Animal Breeding and Genetics, Unit of Functional Cancer Genomics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Lagger, S $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Kenner, L $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria. Lukas.kenner@meduniwien.ac.at $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria. Lukas.kenner@meduniwien.ac.at $u Division of Nuclear Medicine, Medical University of Vienna, 1090, Vienna, Austria. Lukas.kenner@meduniwien.ac.at $u Center for Medical Research (ZMF), Medical University of Graz, 8010, Graz, Austria. Lukas.kenner@meduniwien.ac.at $u CBMed Core Lab, Medical University of Vienna, 1090, Vienna, Austria. Lukas.kenner@meduniwien.ac.at $u Christian Doppler Laboratory of Applied Metabolomics, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, 1090, Vienna, Austria. Lukas.kenner@meduniwien.ac.at
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 21, č. 1 (2022), s. 172
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36045346 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240516120025 $b ABA008
999    __
$a ok $b bmc $g 1854443 $s 1175998
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 21 $c 1 $d 172 $e 20220831 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace